Drugs / setrobuvir
setrobuvir
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01714154 | Nov 2012 → May 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01612143 | Jun → Sep 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00782353 | Oct 2008 → Mar 2009 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01903954 | Jan 2011 → May 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00978497 | Sep 2009 → Apr 2010 | hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01628094 Background | Jun 2012 → Nov 2013 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | setrobuvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01714154 ↗ |
| Known as | ANA598 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00978497 ↗ |
| Known as | RO5466731 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01628094 ↗ |
| Known as | STV | “A Randomized, Open-label, Single Dose, Cross-over Study to Investigate the Relative Bioavailability of Setrobuvir (STV) Tablet Formulation Versus the Reference Setrobuvir...” NCT01612143 ↗ |
| Action | Inhibit | “setrobuvir (a non-nucleoside HCV polymerase inhibitor)” PMID 25456558 ↗ Nov 2014 |
| Modality | Small molecule | “setrobuvir (a non-nucleoside HCV polymerase inhibitor)” PMID 25456558 ↗ Nov 2014 |
| Route | Oral | “ANA598, administered orally twice daily for 3 days” NCT00782353 ↗ |